| Autor: |
Wu F; Department of Radiology, Cleveland Clinic, 9500 Euclid Ave, Cleveland, OH 44195., Bernard S; Brooke Army Medical Center, Fort Sam Houston, TX., Fayad LM; The Russell H. Morgan Department of Radiology and Radiological Science, The Johns Hopkins School of Medicine, Baltimore, MD., Ilaslan H; Department of Radiology, Cleveland Clinic, 9500 Euclid Ave, Cleveland, OH 44195., Messiou C; The Royal Marsden Hospital and The Institute of Cancer Research, London, UK., Moulopoulos LA; School of Medicine, National and Kapodistrian University of Athens Areteion Hospital, Athens, Greece., Mulligan ME; University of Maryland School of Medicine, Baltimore, MD. |
| Abstrakt: |
Advances in the understanding and treatment of multiple myeloma have led to the need for more sensitive and accurate imaging of intramedullary and extramedullary disease. This role of imaging is underscored by recently revised imaging recommendations of the International Myeloma Working Group (IMWG). This narrative review discusses these recommendations from the IMWG for different disease stages, focusing on advanced whole-body modalities, and addresses related challenges and controversies. In the recommendations, whole-body low-dose CT is central in initial patient assessment, replacing the conventional skeletal survey. Although the recommendations favor MRI for diagnosis because of its superior sensitivity and utility in identifying myeloma-defining events, FDG PET/CT is recommended as the modality of choice for assessing treatment response. Consensus opinions are offered regarding the role of imaging in multiple myeloma for characterization of disease distribution, determination of prognosis, and response evaluation. |
